HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gammon, D. C. Articles by Whalen, G. F. Search for Related Content PubMed PubMed Citation Articles by Gammon, D. C. Articles by Whalen, G. F.

DAVID C. GAMMON, B.S.PHARM., is Pharmacy Consultant II, Clinical Pharmacy Services, Commonwealth Medicine, University of Massachusetts Medical School, Worcester; at the time of writing he was Clinical Oncology Pharmacist, Department of Pharmacy, UMassMemorial Medical Center (UMMC)—University Campus, Worcester. VENU G. PILLARISETTY, M.D., is Assistant Professor of Surgery, University of Washington, Seattle; at the time of writing he was Surgical Oncology Fellow, Department of Surgery, UMMC. BILAL PIPERDI, M.D., is Medical Oncologist, Department of Oncology, UMMC. TRACI DUTTON is Pharm.D. candidate, Massachusetts College of Pharmacy and Health Sciences (MCPHS), Worcester. JASON ZYBERT is Pharm.D. candidate, MCPHS. STEVEN H. WOLFE, B.S.PHARM., is Clinical Oncology Pharmacist, UMMC—University Campus. ERIN NGUYEN is Pharm.D. candidate and DALIA SBAT is Pharm.D. candidate, MCPHS. MARY SULLIVAN, M.S., RN, ANP, is Patient Coordinator, Department of Surgery; and GILES F. WHALEN, M.D., is Chief, Division of Surgical Oncology and Endocrine Surgery, UMMC.

Address correspondence to Mr. Gammon at Clinical Pharmacy Services, Commonwealth Medicine, University of Massachusetts Medical School, 33 South Street, Shrewsbury, MA 01545 (David.gammon{at}umassmed.edu).

Purpose. Cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of peritoneal carcinomatosis (PC) in 15 patients are described. Summary. Fifteen patients with PC who were treated with CS and IPHC were retrospectively identified between January 2002 and December 2006. All patients underwent cytoreduction immediately followed by IPHC with mitomycin or cisplatin. The time between undergoing CS and IPHC and the date of the last follow-up appointment or the date of death was used to calculate survival data for each patient. Nine patients had complete cytoreduction, and all but one patient had evidence of invasive disease at the time of surgery. Eleven patients required concomitant bowel resection at the time of debulking. Thirteen patients required blood transfusions during the perioperative period. Nine patients were discharged home, and four were discharged to a rehabilitation facility. Two patients died during the perioperative hospital admission, both of whom had a preoperative Eastern Cooperative Oncology Group (ECOG) performance status score of 2. The median survival time was 8.4 months, similar to the findings of previously published studies. Further studies are needed to see if tumor type, ECOG performance status score, degree of cytoreduction, and the chemotherapy agent used in IPHC can be correlated to quality of life and survival in patients with heterogeneous primary sources of intraabdominal malignancies. Conclusion. Combination treatment with CS followed by IPHC in 15 patients with heterogeneous primary sources of intraabdominal malignancies resulted in a median survival time of 8.4 months. Index terms: Antineoplastic agents; Cisplatin; Hyperthermia; Mitomycin; Peritoneal neoplasms; Quality of life; Surgery